SCHEMBL1102693

SCHEMBL1102693

Cc1cc(C)c(C)c(-c2c3ccccc3c(-c3ccc4ccccc4c3)c3ccncc23)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.43
CYP11B2 P19099 4/20 0.43
CYP17A1 P05093 1/20 0.43
CYP19A1 P11511 1/20 0.43
MAPK9 P45984 5/20 0.39
MAPK10 P53779 5/20 0.39
IKBKB O14920 1/20 0.38
TDO2 P48775 2/20 0.38
GRM1 Q13255 1/20 0.38
MAPK8 P45983 3/20 0.37
SLC22A12 Q96S37 1/20 0.36
CCNC P24863 2/20 0.36
CDK8 P49336 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
TOP2A P11388 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102760 0.91 CYP11B1 (0.44) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL1102481 0.87 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL1102635 0.87 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL1102711 0.86 CYP11B1 (0.45) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL1103648 0.86 CYP11B1 (0.47) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL1102950 0.86 CYP11B2 (0.57) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL1102895 0.86 CYP11B1 (0.53) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL1102717 0.86 CYP11B2 (0.57) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL1102632 0.86 KDM4E (0.42) CYP11B1CYP11B2IKBKBTDO2CYP1A2
SCHEMBL1103677 0.86 CYP11B1 (0.56) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 CYP11B1 836/4885CYP11B2 652/4885CYP17A1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.